Abstract
We performed fine epitope mapping of the CD4+ responses in the ALVAC-HIV-AIDSVAX B/E prime-boost regimen in the Thai Phase III trial (RV144). Non-transformed Env-specific T cell lines established from RV144 vaccinees were used to determine the fine epitope mapping of the V2 and C1 responses and the HLA class II restriction. Data showed that there are two CD4+ epitopes contained within the V2 loop: one encompassing the α4β7 integrin binding site (AA179-181) and the other nested between two previously described genetic sieve signatures (AA169, AA181). There was no correlation between the frequencies of CD4+ fine epitope responses and binding antibody.
Publication types
-
Clinical Trial, Phase III
-
Multicenter Study
-
Randomized Controlled Trial
-
Research Support, Non-U.S. Gov't
-
Research Support, U.S. Gov't, Non-P.H.S.
MeSH terms
-
AIDS Vaccines / immunology*
-
Adolescent
-
Adult
-
Binding Sites, Antibody / immunology*
-
CD4-Positive T-Lymphocytes / immunology*
-
Cell Line
-
Epitope Mapping
-
Female
-
HIV Antibodies / immunology*
-
HIV-1 / immunology*
-
Humans
-
Immunodominant Epitopes / immunology*
-
Male
-
Young Adult
Substances
-
AIDS Vaccines
-
AIDSVAX
-
AIDSVAX B-E
-
HIV Antibodies
-
Immunodominant Epitopes
Grants and funding
This work was funded by the cooperative agreement (W81XWH-07-2-0067) between the Henry M. Jackson Foundation for the Advancement of Military Medicine and the U.S. Department of Defense. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The views expressed herein are those of the authors and should not be construed to represent the positions of the U.S. Army or Department of Defense.